The World's Only Non-Catabolic Pre-workout Energy Supplement!



DRIVE will power you through your most extreme workout. Unlike most pre-workout supplements that are based entirely on caffeine and stimulants, DRIVE will supply you with a sustained energy that lasts up to five hours without jitters or adrenal overload - and best of all, no crash!

DRIVE will:

  • INCREASE ENDURANCE BY 159%!
  • DECREASE FATIGUE BY 26%!
  • IMPROVE SPEED AND STRENGTH!
  • boost alertness
  • improve mood
  • increase focus
  • amplify physical performance
  • promote cell volumization
  • alleviate muscle fatigue
  • increase exercise capacity
  • quicken reflexes
  • improve body coordination
  • decrease stress
  • improve memory
  • strengthen brain health






DRIVE™ is taken 30 minutes before training. DRIVE will unclutter your brain allowing you to feel alert and awake. The "mind-muscle connection" is now a reality. The longer you use DRIVE, the better the effects.

Bodybuilders stack DRIVE with GP3™ and ALPHA™ for the most productive and growth-producing workouts possible.


Taurine - increases cell volumization and decreases muscle fatigue.

Rhodiola Rosea - improves physical and mental performance.

Caffeine - elevates epinephrine/adrenaline, dopamine and serotonin.

Vinpocetine - promotes cerebral circulation.

B-Vitamins - ramp up mood and cognitive functions.






When do I take DRIVE™?
Whenever you need enhanced focus, energy and endurance. Bodybuilders take 2 capsules 30 minutes prior to training stacked with GP3. Many people take DRIVE first thing in the morning before breakfast to power them through their day. Students take DRIVE 45 minutes before a grueling studying session or exam. MMA fighters take it 30-45 minutes before their fight and before all of their training sessions. .


Can I take DRIVE with food?
We recommend taking DRIVE 20 minutes prior to eating or on an empty stomach.


Will I lose weight with DRIVE?
DRIVE is not designed as a fat burner, but could be used to manage weight if taken twice a day.


I get a fantastic euphoric feeling when I use DRIVE. Is this normal?
DRIVE was formulated to boost mood and decrease stress as well as provide hours of clean energy. The results are different in everyone, as with any supplement, but many do experience the euphoric feeling you're referring to.

 Do I have to cycle DRIVE?
No. The longer you use DRIVE the better the results.


Are there any long-term negative side effects?
The ingredients in DRIVE have been carefully researched for their effectiveness and safety. There are no known negative side effects from any of the ingredients. In fact, DRIVE has proven to be very effective for increasing overall brain health.


What results can I expect with DRIVE?
After about 15 minutes you will notice your head begin to clear and your energy will increase. In 30-45 minutes you will notice that your thoughts are organized, your sight and hearing become enhanced and your mood will lift. Stress no longer saps your energy and the world no longer seems as daunting. For 3-6 hours you will have much more energy (as though you've slept a full 10 hours the night before) and you will go through your day with enhanced productivity. After this period, the effects will slowly dissipate and you will return to your "every day" state. There are none of the side effects (no crash, no jitters and no sweats) normally associated with energy supplements.



Research supporting DRIVE: 1. Tsuboyama-Kasaoka, Nobuyo; Chikako Shozawa, Kayo Sano, Yasutomi Kamei, Seiichi Kasaoka, Yu Hosokawa and Osamu Ezaki (2006). "Taurine (2-Aminoethanesulfonic Acid) Deficiency Creates a Vicious Circle Promoting Obesity". Endocrinology 147 (7): 3276–3284. 2. Li F, Abatan OI, Kim H, Burnett D, Larkin D, Obrosova IG, Stevens MJ (2006 Jun). "Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats.". Neurobiology of Disease 22 (3). 3. Pop-Busui R, Sullivan KA, Van Huysen C, Bayer L, Cao X, Towns R, Stevens MJ (2001 Apr). "Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits.". Exp Neurol. 168 (2). 4. Kong WX, Chen SW, Li YL, et al (2006). "Effects of taurine on rat behaviors in three anxiety models". Pharmacol. Biochem. Behav. 83 (2): 271–6. 5. U. Warskulat, U. Flogel, C. Jacoby, H.-G. Hartwig, M. Thewissen, M. W. Merx, A. Molojavyi, B. Heller-Stilb, J. Schrader and D. Haussinger (2004). "Taurine transporter knockout depletes muscle taurine levels and results in severe skeletal muscle impairment but leaves cardiac function uncompromised". FASEB J.: 03-0496fje. 6. “Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes". American Journal of Clinical Nutrition 71 (1): 54-58. 7. Nordic Journal of Psychiatry, 2007 V. 61, No. 5, "SHR-5 Rhodiola rosea and the Treatment of Depression" by V.Darbinyan, G.Aslanyan, E.Amroyan, E.Gabrielyan , C.Malmstro, A.Panossian, The PBM Clinic, Institute of Health Competence, Stockholm-Globen, Sweden 8. Science News Online, Warming to a Cold War Herb 9. American Botanical Council, Rhodiola rosea: A Phytomedicinal Overview 10. Whole Health MD, Reference Library 11. Alternative Medicine, The Herb that Came In from the Cold 12. Nehlig, A; Daval JL, Debry G (1992 May-Aug). "Caffeine and the central nervous system: Mechanisms of action, biochemical, metabolic, and psychostimulant effects". Brain Res Rev 17 (2): 139-70. 13. Fisone G, G; Borgkvist A, Usiello A (2004 April). "Caffeine as a psychomotor stimulant: mechanism of action". Cell Mol Life Sci 61 (7–8): 857-72 14. Graham T, Rush J, van Soeren M (1994). "Caffeine and exercise: metabolism and performance.". Can J Appl Physiol 19 (2): 111-38. 15. redholm B, Bättig K, Holmén J, Nehlig A, Zvartau E (1999). "Actions of caffeine in the brain with special reference to factors that contribute to its widespread use.". Pharmacol Rev 51 (1): 83–133. 16. Dews, P.B. (1984). Caffeine: Perspectives from Recent Research. Berlin: Springer-Valerag. 17. Balestreri R, Fontana L, Astengo, F. (1987) A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc, 35(5): 425-430. 18. Bhatti JZ, Hindmarch I. (1987) Vinpocetine Effects on Cognitive Impairments Produced by Flunitrazepam. Inter Clin Psychopharmacology, 2: 325-331. 19. Bonoczk P, Gulyas B, Adam-Vizi V, et al. (2000) Role of sodium chanel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull, 53(3): 245-54. 20. Burtsev EM, Savkov VS, Shprakh VV, Burtsev, ME. (1992) 10-years experience with using Cavinton in cerebrovascular disorders. Zh Nevropatol Psikhiatr Im S S Korsakova, 92(1): 56-60. 21. Hindmarch I, Fuchs HH, Erzigkeit H. (1991) Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol, 6(1): 31-43. 22. Kiss B, Karpati E. (1996) Mechanism of action of vinpocetine. Acta Pharm Hung, 66 (5): 213-24. 23. Maslarova J, Nikolov R. (1999) Antihypoxic effect of vinpocetine. Works of the Chemical Pharmaceutical Research Institute, XIX, 175-182 (In Bulgarian). 24. Orosz E, Deak Gy, Benoist,Gy. (1976) Effect of ethyl apovincaminate on the cerebral circulation. Arzneim-Forsch, 26(10a): 1951-56. 25. Pálosi É, Szporny L. (1976) Effect of ethyl apovincaminate of the central nervous system. Arzneim-Forsch, 26(10a): 1926-29. 26. Tamaki N, Kusunoki T, Matsumoto S. (1985) The effect of vinpocetine on cerebral blood flow in patients with cerebrovascular disordes. Therapia Hungarica, 33:13-21. 27. Victor Herbert (1988). "Vitamin B-12: plant sources, requirements, and assay 28. Jane Higdon, "Niacin", Micronutrient Information Center, Linus Pauling Institute 29. Katzung, Basic and Clinical Pharmacology, 9th ed. p. 570 30. NIH Medline Plus: Niacin. http://www.nlm.nih.gov/medlineplus/ency/article/002409.htm 31. Kamen B (1997). "Folate and antifolate pharmacology". Seminars in oncology 24 (5 Suppl 18): S18-30-S18-39 32. Coppen A, Bolander-Gouaille C. (2005). "Treatment of depression: time to consider folic acid and vitamin B12". Journal of Psychopharmacology 19 (1): 59-65. 33. Taylor MJ, Carney SM, Goodwin GM, Geddes JR. (2004). "Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials". Journal of Psychopharmacology 18 (2): 251-6 34. "ScientistLive Website". American Journal of Epidemiology. 35. Dr Jane Durga, Martin PJ van Boxtel, Prof Evert G Schouten, Prof Frans J Kok, Prof Jelle Jolles, Martijn B Katan, and Petra Verhoef Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial The Lancet 2007; 369:208-216 36. Council of Experts. USP/NF. 2006 Ed. Rockville, MD: The United States Pharmacopeial Convention; 2005